Risk prediction of atrial fibrillation and its complications in the community using hs troponin I
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Risk prediction of atrial fibrillation and its complications in the community using hs troponin I. / Börschel, Christin S.; Geelhoed, Bastiaan; Niiranen, Teemu; Camen, Stephan; Donati, Maria Benedetta; Havulinna, Aki S.; Gianfagna, Francesco; Palosaari, Tarja; Jousilahti, Pekka; Kontto, Jukka; Vartiainen, Erkki; Ojeda, Francisco M.; den Ruijter, Hester M.; Costanzo, Simona; de Gaetano, Giovanni; Di Castelnuovo, Augusto; Linneberg, Allan; Vishram-Nielsen, Julie K.; Løchen, Maja Lisa; Koenig, Wolfgang; Jørgensen, Torben; Kuulasmaa, Kari; Blankenberg, Stefan; Iacoviello, Licia; Zeller, Tanja; Söderberg, Stefan; Salomaa, Veikko; Schnabel, Renate B.
I: European Journal of Clinical Investigation, Bind 53, Nr. 5, e13950, 2023.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Risk prediction of atrial fibrillation and its complications in the community using hs troponin I
AU - Börschel, Christin S.
AU - Geelhoed, Bastiaan
AU - Niiranen, Teemu
AU - Camen, Stephan
AU - Donati, Maria Benedetta
AU - Havulinna, Aki S.
AU - Gianfagna, Francesco
AU - Palosaari, Tarja
AU - Jousilahti, Pekka
AU - Kontto, Jukka
AU - Vartiainen, Erkki
AU - Ojeda, Francisco M.
AU - den Ruijter, Hester M.
AU - Costanzo, Simona
AU - de Gaetano, Giovanni
AU - Di Castelnuovo, Augusto
AU - Linneberg, Allan
AU - Vishram-Nielsen, Julie K.
AU - Løchen, Maja Lisa
AU - Koenig, Wolfgang
AU - Jørgensen, Torben
AU - Kuulasmaa, Kari
AU - Blankenberg, Stefan
AU - Iacoviello, Licia
AU - Zeller, Tanja
AU - Söderberg, Stefan
AU - Salomaa, Veikko
AU - Schnabel, Renate B.
N1 - Publisher Copyright: © 2023 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
PY - 2023
Y1 - 2023
N2 - Aims: Atrial fibrillation (AF) is becoming increasingly common. Traditional cardiovascular risk factors (CVRF) do not explain all AF cases. Blood-based biomarkers reflecting cardiac injury such as high-sensitivity troponin I (hsTnI) may help close this gap. Methods: We investigated the predictive ability of hsTnI for incident AF in 45,298 participants (median age 51.4 years, 45.0% men) across European community cohorts in comparison to CVRF and established biomarkers (C-reactive protein, N-terminal pro B-type natriuretic peptide). Results: During a median follow-up of 7.7 years, 1734 (3.8%) participants developed AF. Those in the highest hsTnI quarter (≥4.2 ng/L) had a 3.91-fold (95% confidence interval (CI) 3.30, 4.63; p <.01) risk for developing AF compared to the lowest quarter (<1.4 ng/L). In multivariable-adjusted Cox proportional hazards models a statistically significant association was seen between hsTnI and AF (hazard ratio (HR) per 1 standard deviation (SD) increase in log10(hsTnI) 1.08; 95% CI 1.01, 1.16; p =.03). Inclusion of hsTnI did improve model discrimination (C-index CVRF 0.811 vs. C-index CVRF and hsTnI 0.813; p <.01). Higher hsTnI concentrations were associated with heart failure (HR per SD 1.37; 95% CI 1.12, 1.68; p <.01) and overall mortality (HR per SD 1.24; 95% CI 1.09, 1.41; p <.01). Conclusion: hsTnI as a biomarker of myocardial injury does not improve prediction of AF incidence beyond classical CVRF and NT-proBNP. However, it is associated with the AF-related disease heart failure and mortality likely reflecting underlying subclinical cardiovascular impairment.
AB - Aims: Atrial fibrillation (AF) is becoming increasingly common. Traditional cardiovascular risk factors (CVRF) do not explain all AF cases. Blood-based biomarkers reflecting cardiac injury such as high-sensitivity troponin I (hsTnI) may help close this gap. Methods: We investigated the predictive ability of hsTnI for incident AF in 45,298 participants (median age 51.4 years, 45.0% men) across European community cohorts in comparison to CVRF and established biomarkers (C-reactive protein, N-terminal pro B-type natriuretic peptide). Results: During a median follow-up of 7.7 years, 1734 (3.8%) participants developed AF. Those in the highest hsTnI quarter (≥4.2 ng/L) had a 3.91-fold (95% confidence interval (CI) 3.30, 4.63; p <.01) risk for developing AF compared to the lowest quarter (<1.4 ng/L). In multivariable-adjusted Cox proportional hazards models a statistically significant association was seen between hsTnI and AF (hazard ratio (HR) per 1 standard deviation (SD) increase in log10(hsTnI) 1.08; 95% CI 1.01, 1.16; p =.03). Inclusion of hsTnI did improve model discrimination (C-index CVRF 0.811 vs. C-index CVRF and hsTnI 0.813; p <.01). Higher hsTnI concentrations were associated with heart failure (HR per SD 1.37; 95% CI 1.12, 1.68; p <.01) and overall mortality (HR per SD 1.24; 95% CI 1.09, 1.41; p <.01). Conclusion: hsTnI as a biomarker of myocardial injury does not improve prediction of AF incidence beyond classical CVRF and NT-proBNP. However, it is associated with the AF-related disease heart failure and mortality likely reflecting underlying subclinical cardiovascular impairment.
KW - atrial fibrillation
KW - biomarkers
KW - epidemiology
KW - high-sensitivity troponin I
KW - N-terminal pro B-type natriuretic peptide
U2 - 10.1111/eci.13950
DO - 10.1111/eci.13950
M3 - Journal article
C2 - 36602448
AN - SCOPUS:85146341064
VL - 53
JO - European Journal of Clinical Investigation, Supplement
JF - European Journal of Clinical Investigation, Supplement
SN - 0960-135X
IS - 5
M1 - e13950
ER -
ID: 334263512